Kartos Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
275 Shoreline Dr Ste 300, Redwood City, ...Phone Number
(650) 542-0130Website
www.kartosthera.comRevenue
<$5 MillionIndustry
About Kartos Therapeutics
Kartos Therapeutics is a clinical stage biopharmaceutical company focused on developing novel, targeted therapeutics to improve the lives of cancer patients. Their primary product is navtemadlin (KRT-232), an investigational MDM2 inhibitor designed to target the MDM2-p53 interaction, offering potential new treatment options for various solid tumors and hematological malignancies. The company is dedicated to advancing breakthrough therapies through active clinical studies. Their intended clients include patients suffering from cancer who may benefit from innovative treatment solutions.Explore more
Kartos Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Kartos Therapeutics
Compare insights from companies similar to Kartos Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Kartos Therapeutics Tech Stack
A closer look at the technologies used by Kartos Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kartos Therapeutics
Sign Up For FreeTo access detailed company insights
Kartos Therapeutics is a clinical stage biopharmaceutical company focused on developing novel, targeted therapeutics to improve the lives of cancer patients. Their primary product is navtemadlin (KRT-232), an investigational MDM2 inhibitor designed to target the MDM2-p53 interaction, offering potential new treatment options for various solid tumors... Read More
